606 related articles for article (PubMed ID: 17674349)
1. Multiplicity and flexibility in clinical trials.
Brannath W; Koenig F; Bauer P
Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
[TBL] [Abstract][Full Text] [Related]
2. Power and sample size when multiple endpoints are considered.
Senn S; Bretz F
Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
[TBL] [Abstract][Full Text] [Related]
3. The advantages and disadvantages of adaptive designs for clinical trials.
Bauer P; Brannath W
Drug Discov Today; 2004 Apr; 9(8):351-7. PubMed ID: 15081962
[TBL] [Abstract][Full Text] [Related]
4. Issues in designing flexible trials.
Posch M; Bauer P; Brannath W
Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
[TBL] [Abstract][Full Text] [Related]
5. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
6. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
7. Selection and bias--two hostile brothers.
Bauer P; Koenig F; Brannath W; Posch M
Stat Med; 2010 Jan; 29(1):1-13. PubMed ID: 19844944
[TBL] [Abstract][Full Text] [Related]
8. Estimation in flexible two stage designs.
Brannath W; König F; Bauer P
Stat Med; 2006 Oct; 25(19):3366-81. PubMed ID: 16220489
[TBL] [Abstract][Full Text] [Related]
9. Adaptive Dunnett tests for treatment selection.
Koenig F; Brannath W; Bretz F; Posch M
Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
[TBL] [Abstract][Full Text] [Related]
10. Optimized multi-stage designs controlling the false discovery or the family-wise error rate.
Zehetmayer S; Bauer P; Posch M
Stat Med; 2008 Sep; 27(21):4145-60. PubMed ID: 18444249
[TBL] [Abstract][Full Text] [Related]
11. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
12. Implementing type I & type II error spending for two-sided group sequential designs.
Rudser KD; Emerson SS
Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
[TBL] [Abstract][Full Text] [Related]
13. Constructing multiple test procedures for partially ordered hypothesis sets.
Edwards D; Madsen J
Stat Med; 2007 Dec; 26(28):5116-24. PubMed ID: 17476650
[TBL] [Abstract][Full Text] [Related]
14. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
15. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
16. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
17. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
18. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
19. Efficient group sequential designs when there are several effect sizes under consideration.
Jennison C; Turnbull BW
Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
[TBL] [Abstract][Full Text] [Related]
20. Are flexible designs sound?
Burman CF; Sonesson C
Biometrics; 2006 Sep; 62(3):664-9; discussion 670-83. PubMed ID: 16984302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
